Evaxion A/S (EVAX) stock
EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 2/30
$2.77+0.03 (+1.09%)
Close on Nov 16, 2026Market cap $23.10MP/E –Yield –
Evaxion A/S EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2023 it was -$0.81. The highest annual figure on record is -$0.43 in fiscal 2018.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$0.81 | – |
| FY2022 | Dec 31, 2022 | -$0.98 | – |
| FY2021 | Dec 31, 2021 | -$1.26 | – |
| FY2020 | Dec 31, 2020 | -$0.97 | – |
| FY2019 | Dec 31, 2019 | -$0.81 | – |
| FY2018 | Dec 31, 2018 | -$0.43 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | -$0.21 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.20 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.25 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.27 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.36 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.23 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.26 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.24 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.20 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?